Tempus AI (TEM) shares surged more than 11% on Friday, reaching $50.95 at the time of publication, outpacing both the Nasdaq's 0.86% gain and the healthcare sector's 0.3% advance.

The rally was fueled by several converging catalysts. Clinical results published in Nature Medicine demonstrated that Tempus's PRISM2 AI model performs as a best-in-class tool for cancer detection and prognosis. Peer-reviewed validation in a high-impact journal provides external credibility to Tempus's data-science approach, which has been central to its pitch to clinicians and drugmakers since its founding in 2015. With more than 30% of the float sold short, the upward price pressure likely triggered a short squeeze that amplified the gains.

Tempus also recently reported its first-ever quarterly profit and raised its full-year revenue guidance, bolstering investor confidence. The milestone is notable for a company that went public in June 2024 and has prioritized rapid scaling of its multimodal clinical and genomic dataset over near-term margins.

The broader AI-healthcare sector received an additional lift from Doximity, which posted fiscal Q1 revenue of $156.6 million, surpassing the analyst consensus estimate of $151.7 million. Doximity CEO Jeff Tangney described AI as "up-leveling our business across the board" and characterized the market opportunity from AI as "a real surprise and upside." Sentiment from a sector peer helped lift TEM along with the broader group.

On Thursday, CellCarta announced a strategic collaboration with Tempus, adding the company to its CDx Commercialization Lab Network as its second commercial laboratory partner for oncology companion diagnostics. Companion diagnostics are tests used to identify which patients are likely to respond to specific targeted therapies, making them a critical component in the growing precision-oncology pipeline.

Acquisition Deal Under Watch

The rally also alleviated concerns surrounding Tempus's planned acquisition of Personalis. The agreement includes a clause that could terminate the deal if TEM shares fall below $46. Friday's upward move created a buffer between the current trading price and that threshold.

Technical Picture

From a technical perspective, TEM is trading approximately 5% above its 20-day simple moving average (SMA) of $48.15, suggesting the near-term trend is turning upward. However, the stock remains roughly 13% below its 200-day SMA of $58.31, maintaining longer-term downward pressure.

The 50-day SMA at $51.11 sits just 1.1% above current levels, representing an immediate test of whether the current move can be sustained.

The Relative Strength Index (RSI) stands at 53.87, indicating neutral momentum rather than an overbought condition. A death cross formed in January when the 50-day SMA crossed below the 200-day SMA — a pattern that has historically signaled overhead supply during rallies.

Key support sits at $46.50, while key resistance is at $54.50.

The company carries a heavy debt load and continues to burn cash. Uncertainty surrounding reimbursement for newer offerings such as minimal residual disease testing remains a risk factor on the balance sheet. Minimal residual disease testing detects trace cancer remaining after treatment, a high-growth diagnostic category where Tempus competes with firms like Natera and Guardant Health, and where insurance coverage pathways are still evolving.

Tempus's year-to-date performance stands at -25.71%, with a market capitalization of approximately $7.91 billion.